Skip to main navigation Skip to search Skip to main content

Evaluating the current neuro-oncology capacity in Sub-Saharan Africa: A questionnaire-based survey

  • Francis Zerd
  • , Lateef A. Odukoya
  • , Beverly Cheserem
  • , Kwadwo Darko
  • , Nathalie C. Ghomsi
  • , Gloria S. Kabare
  • , David O. Kamson
  • , Jeanette E. Eckel-Passow
  • , Robert B. Jenkins
  • , Paul Decker
  • , Henry Llewellyn
  • , Gaspar J. Kitange
  • , Andrea O. Akinjo
  • , Kabir B. Badmos
  • , W. Elorm Yevudza
  • , Olufemi Bankole
  • , Olufemi E. Idowu
  • , Abiola Abdulrahman Ayanlaja
  • , Claire Karekezi
  • , Elias Edrick
  • Chukwuyem Ekhator, Victoria M. Katasi, Daniel H. Lachance, Jason Huse, Margreth Magambo, Eyerusalem Banti, Michael Magoha, Advera Ngaiza, Arsene D. Nyalundja, Dominique Higgins, Minda Okemwa, Lawrence Osei-Tutu, Bernard Petershie, Frank J. Minja, Charles C. Anunobi, Arnold B. Etame, Liadi Tiamiyu, Gbetoho Fortuné Gankpe, Ugumba Mussa Kwikima, Kashaigili Heronima, Kristin Schroeder, Thierry Muanza, Desmond A. Brown, Alan Davidson, Ekokobe Fonkem, Teddy Totimeh, James Balogun

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Central nervous system (CNS) tumors are a significant cause of morbidity and mortality in Sub-Saharan Africa (SSA). This project aimed to assess and map out the current neuro-oncology capacity in SSA, brain tumor registries, and biobanks. Methods: This cross-sectional study utilized an online survey to gather data from healthcare professionals involved in CNS tumor care across SSA through the Society for Neuro-Oncology SSA (SNOSSA). The survey captured information on the availability of neuro-oncology practitioners, neuropathology, molecular diagnostics, cancer registries, and biobanking. Results: A total of 145 respondents representing 70 healthcare institutions across 22 countries participated. Of the 70 institutions, specialties included neurosurgery (89%, 62/70), anatomic pathology (74%, 52/70), and medical oncology (71%, 50/70). For radiologic evaluation, 64% (45/70) of responding institutions reported having both CT and MRI. Access to molecular testing through immunohistochemistry or next-generation sequencing was available in 46% (32/70) of responding institutions. Multidisciplinary tumor boards were available for CNS cases in 86% (60/70) of responding institutions. Brain tumor-specific registries were available in 29% (20/70) of responding institutions, and 10% (7/70) maintained brain tumor biorepositories. Conclusion: This study demonstrates that SSA has substantial potential in neuro-oncology care practice capacity and facilities. The most significant gaps were in neuropathology and molecular testing, which makes widespread implementation of the WHO 2021 diagnosis challenging. Understanding the prevalence of CNS tumor subtypes in SSA is difficult due to the low number of brain tumor registries and biobanks.

Original languageEnglish (US)
Pages (from-to)537-548
Number of pages12
JournalNeuro-Oncology Practice
Volume13
Issue number3
DOIs
Publication statusPublished - Jun 2026
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Sub-Saharan Africa
  • brain tumors
  • central nervous system
  • neuro-oncology

Fingerprint

Dive into the research topics of 'Evaluating the current neuro-oncology capacity in Sub-Saharan Africa: A questionnaire-based survey'. Together they form a unique fingerprint.

Cite this